Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGENYSE / NASDAQHealthcareSmall cap

$135.07$0.00 (0.0%)

Last close · Data as of Sep 3, 2026

Market cap
$6.9B
P/E
-26.8x
EV / EBITDA
-23.7x
Revenue
$0.00
ROCE
-31.4%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Apogee Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 3 Sep 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change $0.00 (0.0%) from $135 to $135 · Last close Sep 3, 2026

Best weekday to invest, historically

The same weekly amount in APGE, bought on each weekday since 2023.

News & filings

What Apogee Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 256 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Prices are as of 3 Sep 2026; price-based points are paused until newer prices arrive.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 3 Sep 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.

Read moreShow less

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Shares outstanding
68.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$6.9B
P/E
-26.8x
P/B
7.6x
EV / EBITDA
-23.7x
52-week high
$135.08
52-week low
$36.53

Profitability

ROE
-28.3%
ROCE
-31.4%
ROIC
-28.9%
ROA
-27.3%

Growth

Revenue
$0.00
Net profit growth, 1Y
40.5%
Free cash flow
-$232.6M

Solvency

Current ratio
26.57
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
0.89
Cash / Market cap
1.9%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Apogee Therapeutics, Inc. revenue and net profit by fiscal year
Apogee Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$39.8M
FY2023$0.00-$84.0M
FY2024$0.00-$182.1M
FY2025$0.00-$255.8M

Cash flows

FY2025: -$227.4M from operations, -$232.6M free after investment (dashed).

Apogee Therapeutics, Inc. operating and free cash flow by fiscal year
Apogee Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$16.4M-$16.4M
FY2023-$74.8M-$74.9M
FY2024-$171.2M-$172.3M
FY2025-$227.4M-$232.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$284.2M
Net profit
-$255.8M
Cash from operations
-$227.4M
Free cash flow
-$232.6M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$284.2M-$255.8M-$232.6M-28.3%—+40.5%

Monthly returns

Month-by-month returns of APGE across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$937.1M
Liabilities$33.3M
Equity$903.9M
Paid-in capital$1.5B
Retained earnings-$561.8M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; APGE highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Apogee Therapeutics, Inc., Vaxcyte, Inc., Spyre Therapeutics, Inc., Immunovant, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Apogee Therapeutics, Inc.APGEthis company$6.9B-26.8x7.6x-28.3%-23.7x
HealthEquity, Inc.HQY$7.2B33.4x3.4x10.2%16.1x
Oscar Health, Inc.OSCR$7.1B-16.1x7.3x-45.3%—
Vaxcyte, Inc.PCVX$7.0B-9.2x2.6x-28.5%-7.8x
Spyre Therapeutics, Inc.SYRE$6.8B—9.5x-21.7%—
Arcellx, Inc.ACLX$6.7B-29.4x16.7x-56.9%-30.2x
Immunovant, Inc.IMVT$6.7B-13.3x7.9x-59.3%-10.9x
Lantheus Holdings, Inc.LNTH$6.7B28.7x6.1x21.4%17.2x
Hims & Hers Health, Inc.HIMS$6.5B50.5x12.0x23.7%46.1x
Peer median—-9.2x7.6x-25.1%4.2x

Year-to-date ROI

APGE since 1 January, against earlier years.

Historical volatility

APGE's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$285.6M
Research and developmentResearch And Development$214.7M
Depreciation and amortisationDepreciation And Amortization In Income Statement$1.1M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$1.1M
Depreciation income statementDepreciation Income Statement$1.1M
Total expensesTotal Expenses$285.6M
Pretax incomePretax Income-$255.6M

Learn while you research

Academy chapters picked for Apogee Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →